

April 7, 2026

Dear SMA Community,

We are very pleased to share that on Tuesday, Feb. 10, 2026 the US FDA approved a label expansion for the Evrysdi (risdiplam) tablets. The tablet formulation is now approved for administration (after dispersion in water) via nasogastric (NG) or gastrostomy (G) feeding tubes. With this approval, we remove a meaningful barrier and extend the benefits of the tablet to a broader patient population, enhancing accessibility in daily life.

In addition to the exciting update on the expanded use of the dispersed Evrysdi Tablet via feeding tubes, there is also an update regarding drug interaction. Anti-acid reducing medications (for example, omeprazole) are used to treat conditions like acid reflux. A study in healthy volunteers investigated the effects of taking omeprazole while also taking risdiplam. The results of this study showed that taking risdiplam as a tablet at the same time as omeprazole doesn't change how the drug moves through your body or how well it works. Based on these results, no clinically significant differences are expected with other acid-reducing agents, including H2-receptor antagonists and antacids.

Evrysdi is the only non-invasive (ie, orally administered) SMA therapy and is approved in over 100 countries, with >21,000 people with SMA treated. \*Based on individuals with SMA receiving Evrysdi worldwide as of 2024, more than 13,000 people have been treated globally.

We're thrilled that this label update allows us to bring Evrysdi to even more patients.

Sincerely,

Gina Truslow  
Director, Patient Advocacy Relations  
On behalf of the Genentech SMA Team

## What is Evrysdi?

Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults.

### Important Safety Information

- Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:
  - are pregnant or plan to become pregnant, as Evrysdi may harm your unborn baby. Ask your healthcare provider for advice before taking this medicine are a woman who can become pregnant:
    - Before you start your treatment with Evrysdi, your healthcare provider may test you for pregnancy
    - Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping Evrysdi
    - Pregnancy Registry. There is a pregnancy registry for women who take EVRYSDI during pregnancy. The purpose of this registry is to collect information about the health of the pregnant woman and her baby. If you are pregnant or become pregnant while receiving EVRYSDI, tell your healthcare provider right away. Talk to your healthcare provider about registering with the EVRYSDI pregnancy Registry. Your healthcare provider can enroll you in this registry or you can enroll by calling 1-833-760-1098 or visiting <https://www.evrysdipregnancyregistry.com>.
  - are an adult male. Evrysdi may affect a man's ability to have children (fertility). Ask a healthcare provider for advice before taking this medicine
  - are breastfeeding or plan to breastfeed. It is not known if Evrysdi passes into breast milk and may harm your baby

---

4 Moawad D, et al. Real-world use of risdiplam for the treatment of spinal muscular atrophy in infants under 2 months of age in the US. Presented at Cure SMA Research & Clinical Care Meeting 2023

3 Shapouri S, et al. Real-world treatment with risdiplam in adults with SMA: a multicenter study. Presented at Cure SMA Research & Clinical Care Meeting 2023

2 Salem L, et al. A prospective, observational, long-term post-authorisation effectiveness study of risdiplam in patients with SMA. Presented at Cure SMA Research & Clinical Care Meeting 2023

1 To TM, et al. A cross-sectional examination of outcomes data for risdiplam-treated individuals with SMA using the 2022 CURE SMA community update survey. Presented at Cure SMA Research & Clinical Care Meeting 2023

- Tell your healthcare provider about all the medicines you take
- You should receive Evrysdi from the pharmacy as a liquid. If the medicine in the bottle is a powder, do not use it. Contact your pharmacist for a replacement
- Avoid getting Evrysdi on your skin or in your eyes. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water
- The most common side effects of Evrysdi include:

For later-onset SMA:

- fever
- diarrhea
- rash

For infantile-onset SMA:

- fever
- diarrhea
- rash
- runny nose, sneezing and sore throat (upper respiratory infection)
- lung infection (lower respiratory infection)
- constipation
- vomiting
- cough

These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.

You may report side effects to the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Genentech at 1-888-835-2555.

Please see [accompanying] full [Prescribing Information](#) for additional Important Safety Information.